c) hold consultations with relevant sports organisations;

d) make recommendations to the Parties concerning measures to be taken for the purposes of this Convention;

e) recommend the appropriate measures to keep relevant international organisations and the public informed about the activities undertaken within the framework of this Convention;

f) make recommendations to the Committee of Ministers concerning non-member States of the Council of Europe to be invited to accede to this Convention;

g) make any proposal for improving the effectiveness of this Convention.

2. In order to discharge its functions, the monitoring group may, on its own initiative, arrange for meetings of groups of experts.

Article 12

After each meeting, the monitoring group shall forward to the Committee of Ministers of the Council of Europe a report on its work and on the functioning of the Convention.

Article 13

Amendments to the Articles of the Convention

1. Amendments to the articles of this Convention may be proposed by a Party, the Committee of Ministers of the Council of Europe or the monitoring group.

2. Any proposal for amendment shall be communicated by the Secretary General of the Council of Europe to the States mentioned in Article 14 and to every State which has acceded to or has been invited to accede to this Convention in accordance with the provisions of Article 16.

3. Any amendment proposed by a Party or the Committee of Ministers shall be communicated to the monitoring group at least two months before the meeting at which it is to be considered. The monitoring group shall submit to the Committee of Ministers its opinion on the proposed amendment, where appropriate after consultation with the relevant sports organisations.

4. The Committee of Ministers shall consider the proposed amendment and any opinion submitted by the monitoring group and may adopt the amendment.

5. The text of any amendment adopted by the Committee of Ministers in accordance with paragraph 4 of this article shall be forwarded to the Parties for acceptance.

6. Any amendment adopted in accordance with paragraph 4 of this article shall come into force on the first day of the month following the expiration of a period of one month after all Parties have informed the Secretary General of their acceptance thereof.

Final clauses

Article 14

1. This Convention shall be open for signature by member States of the Council of Europe, other States party to the European Cultural Convention and non-member States which have participated in the elaboration of this Convention, which may express their consent to be bound by:

a) signature without reservation as to ratification, acceptance or approval, or

b) signature subject to ratification, acceptance or approval, followed by ratification, acceptance or approval.

2. Instruments of ratification, acceptance or approval shall be deposited with the Secretary General of the Council of Europe.

Article 15

1. The Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date on which five States, including at least four member States of the Council of Europe, have expressed their consent to be bound by the Convention in accordance with the provisions of Article 14.

2. In respect of any signatory State which subsequently expresses its consent to be bound by it, the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of signature or of the deposit of the instrument of ratification, acceptance or approval.

Article 16

1. After the entry into force of this Convention, the Committee of Ministers of the Council of Europe, after consulting the Parties, may invite to accede to the Convention any non-member State by a decision taken by the majority provided for in Article 20. d) of the Statute of the Council of Europe and by the unanimous vote of the representatives of the Contracting States entitled to sit on the Committee.

2. In respect of any acceding State, the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of the deposit of the instrument of accession with the Secretary General of the Council of Europe.

Article 17

1. Any State may, at the time of signature or when depositing its instrument of ratification, acceptance, approval or accession, specify the territory or territories to which this Convention shall apply.

2. Any State may, at any later date, by a declaration addressed to the Secretary General, extend the application of this Convention to any other territory specified in the declaration. In respect of such territory the Convention shall enter into force on the first day of the month following the expiration of a period of one month after the date of receipt of such declaration by the Secretary General.

3. Any declaration made under the two preceding paragraphs may, in respect of any territory mentioned in such declaration, be withdrawn by a notification addressed to the Secretary General. Such withdrawal shall become effective on the first day of the month following the expiration of a period of six months after the date of receipt of the notification by the Secretary General.

Article 18

1. Any Party may, at any time, denounce this Convention by means of a notification addressed to the Secretary General of the Council of Europe.

2. Such denunciation shall become effective on the first day of the month following the expiration of a period of six months after the date of receipt of the notification by the Secretary General.

Article 19

The Secretary General of the Council of Europe shall notify the Parties, the other member States of the Council of Europe, the other States party to the European Cultural Convention, the non-member States which have participated in the elaboration of this Convention and any State which has acceded or has been invited to accede to it of:

a) any signature in accordance with Article 14;

b) the deposit of any instrument of ratification, acceptance, approval or accession in accordance with Article 14 or 16;

c) any date of entry into force of this Convention in accordance with Articles 15 and 16;

d) any information forwarded under the provisions of Article 9;

e) any report prepared in pursuance of the provisions of Article 12;

f) any proposal for amendment or any amendment adopted in accordance with Article 13 and the date on which the amendment comes into force;

g) any declaration made under the provisions of Article 17;

h) any notification made under the provisions of Article 18 and the date on which the denunciation takes effect;

i) any other act, notification or communication relating to this Convention.

In witness whereof the undersigned, being duly authorised thereto, have signed this Convention.

Done at Strasbourg, the 16th day of November 1989, in English and French, both texts being equally authentic, in a single copy which shall be deposited in the archives of the Council of Europe. The Secretary General of the Council of Europe shall transmit certified copies to each member State of the Council of Europe, to the other States party to the European Cultural Convention, to the non-member States which have participated in the elaboration of this Convention and to any State invited to accede to it.

New reference list2 of prohibited classes of substances and prohibited methods and its Explanatory document

Date of entry into force: 1 January 2003

PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS 2003

I. Prohibited classes of substances

A) Stimulants

a) Prohibited substances in class A) a) include the following examples with both their L-and D-isomers:

amiphenazole, amphetamines, bromantan, caffeine3, carphedon, cocaine, ephedrines4, fencamfamin, mesocarb, pentetrazol, pipradrol, ... and related substances.

Note: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological, rectal) of adrenaline are permitted. Bupropion, synephrine and phenylephrine are permitted.

b) Prohibited substances in class A) b) include the following examples with both their L-and D-isomers:

formoterol5, salbutamol6, salmeterol7 and terbutaline8 ... and related substances

Written notification by a respiratory or team physician that the athlete has asthma and/or exercise-induced asthma is necessary to the relevant medical authority prior to competition. At the Olympics Games, athletes who request permission to inhale a permitted beta-2 agonist, will be assessed by an independent medical panel.

B) Narcotics

Prohibited substances in class B) include the following examples:

buprenorphine, dextromoramide, diamorphine (heroin), methadone, morphine, pentazocine, pethidine,... and related substances.

Note: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate, ethylmorphine, pholcodine, propoxyphene and tramadol are permitted.

C) Anabolic agents

Prohibited substances in class C) include the following examples:

1. Anabolic androgenic steroids

a) clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, ... and related substances;

b) androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone9, ... and related substances.

Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to draw definitive conclusions.

In the case of T/E greater than 6, it is mandatory that the relevant medical authority conducts an investigation before the sample is declared positive. A full report will be written and will include a review of previous tests, subsequent tests and any results of endocrine investigations. In the event that previous tests are not available, the athlete should be tested unannounced at least once per month for three months. The results of these investigations should be included in the report. Failure to co-operate in the investigations will result in declaring the sample positive.

2. Other anabolic agents

clenbuterol, salbutamol10

D) Diuretics

Prohibited substances in class D) include the following examples:

acetazolamide, bumetanide, chlortalidone, etacrynic acid, furosemide, hydrochlorothiazide, mannit11, mersalyl, spironolakton, triamterene, ... and related substances.

E) Peptide hormones, mimetics and analogues

Prohibited substances in class E) include the following examples and their analogues and mimetics:

1. Chorionic Gonadotrophin (hCG) prohibited in males only;

2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only;

3. Corticotrophins (ACTH, tetracosactide);

4. Growth hormone (hGH);

5. Insulin-like Growth Factor (IGF-1); and all the respective releasing factors and their analogues;

6. Erythropoietin (EPO);

7. Insulin12

The term ’insulin-dependent’ is used here to describe people with diabetes in whom insulin treatment is required, in the judgement of a suitably qualified physician. It will always be the case in Type 1 and sometimes in Type 2 diabetes mellitus. Written certification of insulin-dependent diabetes must be obtained from an endocrinologist or team physician.

The presence of an abnormal concentration of an endogenous hormone in class E) or its diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has been proven to be due to a physiological or pathological condition.

F) Agents with anti-oestrogenic activity

Aromatase inhibitors, clomiphene, cyclofenil, tamoxifen are prohibited only in males.

G) Masking agents

Prohibited substances in class G) include the following examples:

diuretics, epitestosterone13, probenecid, plasma expanders (e.g. hydroxyethyl starch).

Masking agents are prohibited. They are products that have the potential to impair the excretion of prohibited substances or to conceal their presence in urine or other samples used in doping control.

II. Prohibited methods

The following procedures are prohibited:

A) Enhancement of oxygen transfer

a) Blood doping. Blood doping is the administration of autologous, homologous or heterologous blood or red blood cell products of any origin, other than for legitimate medical treatment.

b) The administration of products that enhance the uptake, transport or delivery of oxygen, e.g. modified haemoglobin products including but not limited to bovine and cross-linked haemoglobins, microencapsulated haemoglobin products, perfluorochemicals, and RSR13.

B) Pharmacological, chemical and physical manipulation

Pharmacological, chemical and physical manipulation is the use of substances and methods, including masking agents [ref I. G)], which alter, attempt to alter or may reasonably be expected to alter the integrity and validity of specimens collected in doping controls. These include, without limitation, catheterisation, urine substitution and/or tampering, inhibition of renal excretion and alterations of testosterone and epitestosterone [ref I. G)] measurements.

C) Gene doping

Gene or cell doping is defined as the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance.

III. Classes of prohibited substances in certain sports

A) Alcohol

Where the rules of the governing body so provide, tests will be conducted for ethanol.

B) Cannabinoids

Where the rules of the governing body so provide, tests will be conducted for cannabinoids (e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (carboxy-THC) greater than 15 nanograms per millilitre constitutes doping.

C) Local anaesthetics

Injectable local anaesthetics are permitted under the following conditions:

a) bupivacaine, lidocaine, mepivacaine, procaine, and related substances, can be used but not cocaine. Vasoconstrictor agents may be used in conjunction with local anaesthetics;

b) only local or intra-articular injections may be administered;

c) only when medically justified.

Where the rules of the governing body so provide, notification of administration may be necessary.

D) Glucocorticosteroids

The systemic use of glucocorticosteroids is prohibited when administered orally, rectally, or by intravenous or intramuscular injection.

When medically necessary, local and intra-articular injections of glucocorticosteroids are permitted. Where the rules of the governing body so provide, notification of administration may be necessary.

E) Beta-blockers